DEINOVE Logo

DEINOVE

ALDEI | PA

Overview

Corporate Details

ISIN(s):
FR0010879056 (+1 more)
LEI:
969500BEJSRFER0F2K08
Country:
France
Address:
1682 RUE DE LA VALSIERE, 34790 GRABELS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for DEINOVE and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2023-01-24 17:45
Legal Proceedings Report
Conversion de la procédure de redressement judiciaire en liquidation judiciaire
French 80.4 KB
2023-01-24 17:45
Legal Proceedings Report
Conversion of the receivership proceedings into judicial liquidation proceedings
English 67.6 KB
2023-01-16 19:09
Legal Proceedings Report
DEINOVE - Point sur la procédure de redressement judiciaire
French 79.4 KB
2023-01-16 19:09
Legal Proceedings Report
DEINOVE - Update on the receivership proceedings
English 66.5 KB
2022-12-16 18:10
Legal Proceedings Report
DEINOVE - Point sur la Procédure de Redressement Judiciaire
French 80.2 KB
2022-12-16 18:10
Legal Proceedings Report
DEINOVE - Update on the Receivership Proceedings
English 67.5 KB
2022-11-07 17:45
Legal Proceedings Report
Deinove annonce L’ouverture d’une procédure de redressement judiciaire
French 72.0 KB
2022-11-07 17:45
Legal Proceedings Report
Deinove Announces the Opening of Receivership Proceedings
English 89.5 KB
2022-10-28 17:51
Legal Proceedings Report
DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS
English 67.6 KB
2022-10-28 17:51
Legal Proceedings Report
DEINOVE SOLLICITE UNE PROCÉDURE DE REDRESSEMENT JUDICIAIRE
French 68.6 KB
2022-10-20 17:45
Post-Annual General Meeting Information
DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary Genera…
English 69.8 KB
2022-10-20 17:45
Post-Annual General Meeting Information
DEINOVE - Adoption de l'ensemble des résolutions de son Assemblée Générale Extr…
French 71.2 KB
2022-10-10 17:45
Post-Annual General Meeting Information
DEINOVE - Extraordinary General Meeting of October 17, 2022: Appointment of an …
English 86.3 KB
2022-10-10 17:45
Pre-Annual General Meeting Information
DEINOVE- Assemblée générale extraordinaire du 17 octobre 2022 : Désignation d'u…
French 88.2 KB
2022-10-06 19:02
Earnings Release
DEINOVE présente ses résultats financiers et l’avancée de ses programmes pour l…
French 239.0 KB

Automate Your Workflow. Get a real-time feed of all DEINOVE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DEINOVE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN

Talk to a Data Expert

Have a question? We'll get back to you promptly.